Literature DB >> 16362146

Development of the Qualeffo-31, an osteoporosis-specific quality-of-life questionnaire.

N M van Schoor1, D L Knol, C A W Glas, R W J G Ostelo, A Leplège, C Cooper, O Johnell, P Lips.   

Abstract

INTRODUCTION: Vertebral deformities are a common consequence of osteoporosis and are known to decrease quality of life. The Qualeffo-41 is a quality-of-life questionnaire especially developed for measuring quality of life in patients with vertebral deformities. It consists of 41 questions arranged in five domains: pain, physical function, social function, general health perception, and mental function. The objectives of this study were: (1) to develop a shorter version of the Qualeffo-41 by removing redundant questions; and (2) to investigate the scale characteristics, reliability, and validity of this shorter version.
METHODS: The study was performed using data from the Qualeffo validation study and the Multiple Outcomes of Raloxifene Evaluation (MORE) study. The analyses were performed in patients with vertebral deformities (n=579). Factor analysis on polychoric correlations and an item response theory (IRT) model, i.e., the generalized partial credit model (GPCM), were used to create a shorter version of Qualeffo-41. Using GPCM, scoring weights were computed for all items.
RESULTS: Three items were removed from the data set because of too many missing values. Factor analysis identified three instead of five domains: (1) pain, (2) physical function, and (3) mental function. Five items had factor loadings <0.4 and were not included in the GPCM. After excluding several items, the domains pain (four items), physical function (18 items), and mental function (nine items) showed a good, reasonable, and excellent fit, respectively. This indicates that the mental function domain and the pain domain are more unidimensional than the physical function domain. All three domains showed a very high correlation (r > or =0.95) with the corresponding domains of the Qualeffo-41.
CONCLUSIONS: Qualeffo-31 was developed, consisting of three domains with a reasonable to excellent fit to the GPCM. Although the fit to the GPCM supports the construct validity of the Qualeffo-31, validation in a new study should be performed before using it in practice.

Entities:  

Mesh:

Year:  2005        PMID: 16362146     DOI: 10.1007/s00198-005-0024-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  16 in total

1.  Revision of the ICIDH Severity of Disabilities Scale by data linking and item response theory.

Authors:  S van Buuren; M Hopman-Rock
Journal:  Stat Med       Date:  2001-04-15       Impact factor: 2.373

2.  A discussion of item response theory and its applications in health status assessment.

Authors:  D Cella; C H Chang
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

3.  Practical implications of item response theory and computerized adaptive testing: a brief summary of ongoing studies of widely used headache impact scales.

Authors:  J E Ware; J B Bjorner; M Kosinski
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

4.  Item response theory and health outcomes measurement in the 21st century.

Authors:  R D Hays; L S Morales; S P Reise
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

Review 5.  Clinical consequences of vertebral fractures.

Authors:  P D Ross
Journal:  Am J Med       Date:  1997-08-18       Impact factor: 4.965

6.  Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis.

Authors:  P Lips; C Cooper; D Agnusdei; F Caulin; P Egger; O Johnell; J A Kanis; S Kellingray; A Leplege; U A Liberman; E McCloskey; H Minne; J Reeve; J Y Reginster; M Scholz; C Todd; M C de Vernejoul; I Wiklund
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

7.  Figuring out factors: the use and misuse of factor analysis.

Authors:  D L Streiner
Journal:  Can J Psychiatry       Date:  1994-04       Impact factor: 4.356

8.  The clinical consequences of vertebral compression fracture.

Authors:  S L Silverman
Journal:  Bone       Date:  1992       Impact factor: 4.398

9.  Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women.

Authors:  G Jones; C White; T Nguyen; P N Sambrook; P J Kelly; J A Eisman
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

10.  The health consequences of vertebral deformity in elderly Chinese men and women.

Authors:  E M Lau; J Woo; H Chan; M K Chan; J Griffith; Y H Chan; P C Leung
Journal:  Calcif Tissue Int       Date:  1998-07       Impact factor: 4.333

View more
  11 in total

1.  Validation of the Quality-of-Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-26) in Korean population.

Authors:  Jung Sub Lee; Jong Ki Shin; Seung Min Son; Sung Jin An; Sung Shik Kang
Journal:  Rheumatol Int       Date:  2014-01-11       Impact factor: 2.631

2.  The reliability and validity of the simplified Chinese version of Male QUALEFFO-26.

Authors:  Leilei Xu; Weixiang Sun; Xiaodong Qin; Xiufen Zhu; Yong Qiu; Zezhang Zhu
Journal:  Rheumatol Int       Date:  2015-12-22       Impact factor: 2.631

3.  Validation of the simplified Chinese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-31).

Authors:  Chuanwen Zhou; Qianjun Li; Shushu Huang; Lu Fan; Bingjian Wang; Jian Dai; Xiaoming Tang
Journal:  Eur Spine J       Date:  2015-06-14       Impact factor: 3.134

4.  Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-31) in Chinese.

Authors:  Billy M H Lai; Shirley W Y Tsang; Cindy L K Lam; Annie W C Kung
Journal:  Clin Rheumatol       Date:  2010-06-26       Impact factor: 2.980

5.  Validation of the Portuguese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-41) in Brazilian women with postmenopausal osteoporosis with vertebral fracture.

Authors:  Néville de Oliveira Ferreira; Michael Arthuso; Raimunda Beserra da Silva; Aarão Mendes Pinto-Neto; Lúcia Costa-Paiva
Journal:  Clin Rheumatol       Date:  2013-04-23       Impact factor: 2.980

6.  Effects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study.

Authors:  Alfredo Ceballos; Gladys Castaño; Sarahí Mendoza; Juan González; Rosa Mas; Lilia Fernández; José Illnait; Meilis Mesa; Rafael Gámez; Julio César Fernández; Ricardo Telles; Duany Marrero; Mainel Gómez Eng; Dalmer Ruiz; Yunaisi Jardines
Journal:  Korean J Intern Med       Date:  2011-06-01       Impact factor: 3.165

7.  The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: A clinical trial study.

Authors:  Feyzi Gokosmanoglu; Ceyhun Varim; Aysegul Atmaca; Mehmet Hulusi Atmaca; Ramis Colak
Journal:  J Res Med Sci       Date:  2016-11-07       Impact factor: 1.852

8.  Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis.

Authors:  Alissa Walsh; Rena Cao; Darren Wong; Ramona Kantschuster; Lawrence Matini; Jean Wilson; Andrey Kormilitzin; Matthew South; Simon Travis; Sarah Bauermeister
Journal:  BMC Gastroenterol       Date:  2021-03-22       Impact factor: 3.067

9.  Validation of the IOF quality of life questionnaire for patients with wrist fracture.

Authors:  P Lips; K Jameson; M L Bianchi; S Goemaere; S Boonen; J Reeve; J Stepan; O Johnell; N M van Schoor; E Dennison; J A Kanis; C Cooper
Journal:  Osteoporos Int       Date:  2009-06-06       Impact factor: 4.507

Review 10.  Quality of life measurements in patients with osteoporosis and fractures.

Authors:  Melisa M Madureira; Rozana M Ciconelli; Rosa M R Pereira
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.